Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pulmonary Arterial Hypertension - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2016', provides an overview of the Pulmonary Arterial Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension - The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects - The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Pulmonary Arterial Hypertension Overview 9 Therapeutics Development 10 Pipeline Products for Pulmonary Arterial Hypertension - Overview 10 Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis 11 Pulmonary Arterial Hypertension - Therapeutics under Development by Companies 12 Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes 16 Pulmonary Arterial Hypertension - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Pulmonary Arterial Hypertension - Products under Development by Companies 20 Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes 24 Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 25 APT Therapeutics, Inc. 25 Arena Pharmaceuticals, Inc. 26 Asahi Kasei Pharma Corp. 27 Ascendis Pharma A/S 28 Bial - Portela & Ca, S.A. 29 Bristol-Myers Squibb Company 30 Carolus Therapeutics, Inc. 31 Celsion Corporation 32 Complexa, Inc. 33 Corridor Pharmaceuticals Inc. 34 Cytokinetics, Inc. 35 Eli Lilly and Company 36 F. Hoffmann-La Roche Ltd. 37 Gilead Sciences, Inc. 38 Insmed Incorporated 39 INVENT Pharmaceuticals, Inc. 40 Johnson & Johnson 41 Kowa Company, Ltd. 42 Mallinckrodt Plc 43 Mezzion Pharma Co. Ltd. 44 miRagen Therapeutics, Inc. 45 Morphogen-IX Limited 46 Nippon Kayaku Co., Ltd. 47 Nippon Shinyaku Co., Ltd. 48 Novartis AG 49 Peloton Therapeutics, Inc. 50 PharmaIN Corporation 51 PhaseBio Pharmaceuticals, Inc. 52 Pluristem Therapeutics Inc. 53 Proteo, Inc. 54 Pulmokine, Inc. 55 Reata Pharmaceuticals, Inc. 56 Respira Therapeutics, Inc. 57 Selten Pharma, Inc 58 Silence Therapeutics Plc 59 SteadyMed Therapeutics, Inc. 60 Suda Ltd 61 Toray Industries, Inc. 62 Pulmonary Arterial Hypertension - Therapeutics Assessment 63 Assessment by Monotherapy Products 63 Assessment by Target 64 Assessment by Mechanism of Action 68 Assessment by Route of Administration 71 Assessment by Molecule Type 73 Drug Profiles 75 Antibody for Pulmonary Arterial Hypertension - Drug Profile 75 Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 76 APT-602 - Drug Profile 77 bardoxolone methyl - Drug Profile 78 beraprost sodium ER - Drug Profile 81 beraprost sodium SR - Drug Profile 82 BIA-51058 - Drug Profile 83 BMP-9 - Drug Profile 84 CT-2009 - Drug Profile 85 CXA-10 - Drug Profile 86 Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile 87 fasudil - Drug Profile 88 imatinib mesylate - Drug Profile 89 INS-1009 - Drug Profile 92 INV-240 - Drug Profile 93 JNJ-26993135 - Drug Profile 94 lisuride - Drug Profile 95 MFC-001 - Drug Profile 97 MFC-002 - Drug Profile 98 nitric oxide - Drug Profile 99 Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile 102 Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 103 PB-1046 - Drug Profile 104 PB-1120 - Drug Profile 106 pitavastatin NP - Drug Profile 107 PK-10453 - Drug Profile 108 PK-10571 - Drug Profile 109 PLX-PAD - Drug Profile 110 PT-2977 - Drug Profile 114 QCC-374 - Drug Profile 115 R-190 - Drug Profile 116 ralinepag - Drug Profile 118 RT-234 - Drug Profile 120 selexipag - Drug Profile 121 selonsertib - Drug Profile 123 sirolimus albumin-bound - Drug Profile 124 Small Molecule for Pulmonary Arterial Hypertension - Drug Profile 126 Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 127 Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension - Drug Profile 128 Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 129 Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 130 Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 131 SPI-054 - Drug Profile 132 SPI-183 - Drug Profile 133 SUD-004 - Drug Profile 134 Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction - Drug Profile 135 Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 136 tacrolimus - Drug Profile 137 tadalafil - Drug Profile 138 tiprelestat - Drug Profile 140 tocilizumab - Drug Profile 143 TR-422 - Drug Profile 147 treprostinil - Drug Profile 148 treprostinil diolamine - Drug Profile 149 TXA-127 - Drug Profile 150 ubenimex - Drug Profile 153 udenafil - Drug Profile 154 Pulmonary Arterial Hypertension - Recent Pipeline Updates 156 Pulmonary Arterial Hypertension - Dormant Projects 185 Pulmonary Arterial Hypertension - Discontinued Products 188 Pulmonary Arterial Hypertension - Product Development Milestones 189 Featured News & Press Releases 189 Appendix 197 Methodology 197 Coverage 197 Secondary Research 197 Primary Research 197 Expert Panel Validation 197 Contact Us 197 Disclaimer 198
List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2016 14 Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Development by Companies, H1 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Comparative Analysis by Late Stage Development, H1 2016 21 Comparative Analysis by Clinical Stage Development, H1 2016 22 Comparative Analysis by Early Stage Development, H1 2016 23 Products under Development by Companies, H1 2016 24 Products under Development by Companies, H1 2016 (Contd..1) 25 Products under Development by Companies, H1 2016 (Contd..2) 26 Products under Development by Companies, H1 2016 (Contd..3) 27 Products under Investigation by Universities/Institutes, H1 2016 28 Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H1 2016 29 Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 30 Pulmonary Arterial Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2016 31 Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H1 2016 32 Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H1 2016 33 Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Company, H1 2016 34 Pulmonary Arterial Hypertension - Pipeline by Carolus Therapeutics, Inc., H1 2016 35 Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H1 2016 36 Pulmonary Arterial Hypertension - Pipeline by Complexa, Inc., H1 2016 37 Pulmonary Arterial Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H1 2016 38 Pulmonary Arterial Hypertension - Pipeline by Cytokinetics, Inc., H1 2016 39 Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H1 2016 40 Pulmonary Arterial Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 41 Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H1 2016 42 Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H1 2016 43 Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 44 Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H1 2016 45 Pulmonary Arterial Hypertension - Pipeline by Kowa Company, Ltd., H1 2016 46 Pulmonary Arterial Hypertension - Pipeline by Mallinckrodt Plc, H1 2016 47 Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 48 Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2016 49 Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Limited, H1 2016 50 Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 51 Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 52 Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H1 2016 53 Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics, Inc., H1 2016 54 Pulmonary Arterial Hypertension - Pipeline by PharmaIN Corporation, H1 2016 55 Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 56 Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H1 2016 57 Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H1 2016 58 Pulmonary Arterial Hypertension - Pipeline by Pulmokine, Inc., H1 2016 59 Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 60 Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics, Inc., H1 2016 61 Pulmonary Arterial Hypertension - Pipeline by Selten Pharma, Inc, H1 2016 62 Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H1 2016 63 Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H1 2016 64 Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H1 2016 65 Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H1 2016 66 Assessment by Monotherapy Products, H1 2016 67 Number of Products by Stage and Target, H1 2016 69 Number of Products by Stage and Mechanism of Action, H1 2016 73 Number of Products by Stage and Route of Administration, H1 2016 76 Number of Products by Stage and Molecule Type, H1 2016 78 Pulmonary Arterial Hypertension Therapeutics - Recent Pipeline Updates, H1 2016 160 Pulmonary Arterial Hypertension - Dormant Projects, H1 2016 189 Pulmonary Arterial Hypertension - Dormant Projects (Contd..1), H1 2016 190 Pulmonary Arterial Hypertension - Dormant Projects (Contd..2), H1 2016 191 Pulmonary Arterial Hypertension - Discontinued Products, H1 2016 192
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
